SLC37A3

Summary

SLC37A3 (solute carrier family 37 member 3, HGNC:20651) is a protein-coding gene on chromosome 7q34, encoding Sugar phosphate exchanger 3 (Q8NCC5). Unlike the other SLC37 members, lacks glucose-6-phosphate antiporter activity.

Enables xenobiotic transmembrane transporter activity. Involved in xenobiotic transmembrane transport. Located in endoplasmic reticulum membrane and lysosomal membrane.

Source: NCBI Gene 84255 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa (Strong, GenCC)
• Clinical variants (ClinVar): 97 total
• MANE Select transcript: NM_207113

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20651
Approved symbol	SLC37A3
Name	solute carrier family 37 member 3
Location	7q34
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp761N0624, SPX3
Ensembl gene	ENSG00000157800
Ensembl biotype	protein_coding
OMIM	619137
Entrez	84255

Gene structure

Transcript identifiers

Ensembl transcripts: 44 — 29 protein_coding, 7 retained_intron, 5 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined

ENST00000326232, ENST00000340308, ENST00000447932, ENST00000460560, ENST00000461089, ENST00000462881, ENST00000464834, ENST00000464865, ENST00000467233, ENST00000469193, ENST00000469636, ENST00000473060, ENST00000473707, ENST00000477006, ENST00000477571, ENST00000484416, ENST00000485139, ENST00000485538, ENST00000485734, ENST00000485861, ENST00000487319, ENST00000490760, ENST00000491357, ENST00000491505, ENST00000492027, ENST00000493423, ENST00000495257, ENST00000498469, ENST00000904341, ENST00000904342, ENST00000904343, ENST00000904344, ENST00000937910, ENST00000937911, ENST00000937912, ENST00000937913, ENST00000937914, ENST00000937915, ENST00000937916, ENST00000937917, ENST00000937918, ENST00000952704, ENST00000952705, ENST00000952706

RefSeq mRNA: 9 — MANE Select: NM_207113 NM_001287498, NM_001363373, NM_001363374, NM_001363375, NM_001363376, NM_001363377, NM_001363378, NM_032295, NM_207113

CCDS: CCDS5858, CCDS5859, CCDS75669

Canonical transcript exons

ENST00000326232 — 15 exons

Exon	Start	End
ENSE00001938760	140398416	140398530
ENSE00003465444	140337284	140337349
ENSE00003480994	140355668	140355764
ENSE00003487181	140345869	140345970
ENSE00003495331	140351273	140351451
ENSE00003497782	140358640	140358785
ENSE00003508938	140369590	140369682
ENSE00003571762	140333752	140335504
ENSE00003587166	140343412	140343563
ENSE00003588231	140382438	140382596
ENSE00003617127	140380282	140380390
ENSE00003648289	140364408	140364491
ENSE00003654242	140345216	140345263
ENSE00003784224	140352062	140352146
ENSE00003784247	140348626	140348767

Expression profiles

Bgee: expression breadth ubiquitous, 245 present calls, max score 96.17.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.2579 / max 75.7651, expressed in 1657 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
86549	6.2507	1657
86548	0.0072	3

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of uterus	UBERON:0009853	96.17	gold quality
decidua	UBERON:0002450	95.35	gold quality
smooth muscle tissue	UBERON:0001135	94.48	gold quality
myometrium	UBERON:0001296	94.31	gold quality
colonic epithelium	UBERON:0000397	93.97	gold quality
endocervix	UBERON:0000458	93.78	gold quality
cortical plate	UBERON:0005343	93.65	gold quality
uterus	UBERON:0000995	93.62	gold quality
stromal cell of endometrium	CL:0002255	93.44	gold quality
left uterine tube	UBERON:0001303	93.41	gold quality
endometrium	UBERON:0001295	92.64	gold quality
body of pancreas	UBERON:0001150	92.57	gold quality
mucosa of stomach	UBERON:0001199	92.43	gold quality
uterine cervix	UBERON:0000002	92.22	gold quality
rectum	UBERON:0001052	92.20	gold quality
cartilage tissue	UBERON:0002418	91.79	gold quality
left ovary	UBERON:0002119	91.72	gold quality
ectocervix	UBERON:0012249	91.68	gold quality
muscle layer of sigmoid colon	UBERON:0035805	91.55	gold quality
right ovary	UBERON:0002118	91.43	gold quality
transverse colon	UBERON:0001157	91.33	gold quality
pancreas	UBERON:0001264	91.33	gold quality
colon	UBERON:0001155	91.12	gold quality
large intestine	UBERON:0000059	91.09	gold quality
right uterine tube	UBERON:0001302	91.01	gold quality
ascending aorta	UBERON:0001496	90.96	gold quality
thoracic aorta	UBERON:0001515	90.93	gold quality
gall bladder	UBERON:0002110	90.92	gold quality
colonic mucosa	UBERON:0000317	90.81	gold quality
ileal mucosa	UBERON:0000331	90.81	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

64 targeting SLC37A3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-142-3P	99.62	71.30	974
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-6832-3P	99.52	70.44	1726
HSA-MIR-330-3P	99.41	69.95	2521
HSA-MIR-5580-5P	99.38	66.96	1139

Literature-anchored findings (GeneRIF, showing 1)

• SLC37A3 protein localizes in lysosomes in HeLa cells (PMID:21752829)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
drosophila_melanogaster	dmGlut	FBGN0010497
drosophila_melanogaster	Picot	FBGN0024315
drosophila_melanogaster	CG9254	FBGN0028513
drosophila_melanogaster	CG6978	FBGN0029727
drosophila_melanogaster	MFS16	FBGN0034611
caenorhabditis_elegans		WBGENE00011717
caenorhabditis_elegans		WBGENE00011719

Paralogs (12): SLC17A6 (ENSG00000091664), SLC17A9 (ENSG00000101194), SLC17A7 (ENSG00000104888), SLC17A2 (ENSG00000112337), SLC17A5 (ENSG00000119899), SLC17A3 (ENSG00000124564), SLC17A1 (ENSG00000124568), SLC37A2 (ENSG00000134955), SLC37A4 (ENSG00000137700), SLC17A4 (ENSG00000146039), SLC37A1 (ENSG00000160190), SLC17A8 (ENSG00000179520)

Protein

Protein identifiers

Sugar phosphate exchanger 3 — Q8NCC5 (reviewed: Q8NCC5)

Alternative names: Solute carrier family 37 member 3

All UniProt accessions (16): C9J4S7, C9JZ37, Q8NCC5, F8WAR9, F8WC97, F8WF28, H7C4I4, H7C4J2, H7C4J3, H7C4J5, H7C4U0, H7C4U5, H7C4Z5, H7C594, H7C5E7, H7C5T4

UniProt curated annotations — full annotation on UniProt →

Function. Unlike the other SLC37 members, lacks glucose-6-phosphate antiporter activity. In osteoclasts, forms a transporter complex with ATRAID for nitrogen-containing-bisphophonates (N-BPs) required for releasing N-BP molecules that have trafficked to lysosomes through fluid-phase endocytosis into the cytosol.

Subunit / interactions. Interacts with ATRAID; the interaction is direct and both proteins are mutually dependent for their stability.

Subcellular location. Endoplasmic reticulum membrane. Lysosome membrane.

Tissue specificity. Expressed in liver, kidney, intestine and pancreas.

Post-translational modifications. Glycosylated.

Similarity. Belongs to the major facilitator superfamily. Organophosphate:Pi antiporter (OPA) (TC 2.A.1.4) family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8NCC5-1	1	yes
Q8NCC5-2	2
Q8NCC5-3	3

RefSeq proteins (9): NP_001274427, NP_001350302, NP_001350303, NP_001350304, NP_001350305, NP_001350306, NP_001350307, NP_115671, NP_996996* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000849	Sugar_P_transporter	Family
IPR011701	MFS	Family
IPR020846	MFS_dom	Domain
IPR036259	MFS_trans_sf	Homologous_superfamily

Pfam: PF07690

UniProt features (20 total): transmembrane region 12, splice variant 3, glycosylation site 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NCC5-F1	84.11	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 58, 266

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 149 (showing top): GOCC_VACUOLAR_MEMBRANE, GOBP_INORGANIC_ANION_TRANSPORT, GOBP_XENOBIOTIC_TRANSMEMBRANE_TRANSPORT, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GOBP_PHOSPHATE_ION_TRANSPORT, ACATTCC_MIR1_MIR206, GOBP_ORGANIC_ANION_TRANSPORT, AAAGGGA_MIR204_MIR211, KUNINGER_IGF1_VS_PDGFB_TARGETS_DN, GOBP_CARBOHYDRATE_DERIVATIVE_TRANSPORT, GOBP_TRANSMEMBRANE_TRANSPORT, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, ZHENG_FOXP3_TARGETS_IN_THYMUS_UP, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK

GO Biological Process (2): xenobiotic transmembrane transport (GO:0006855), transmembrane transport (GO:0055085)

GO Molecular Function (3): xenobiotic transmembrane transporter activity (GO:0042910), protein binding (GO:0005515), transmembrane transporter activity (GO:0022857)

GO Cellular Component (5): lysosomal membrane (GO:0005765), endoplasmic reticulum membrane (GO:0005789), lysosome (GO:0005764), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
xenobiotic transport	2
transmembrane transport	2
transport	1
cellular process	1
transmembrane transporter activity	1
binding	1
transporter activity	1
lysosome	1
lytic vacuole membrane	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
lytic vacuole	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

912 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC37A3	ATRAID	Q6UW56	654
SLC37A3	SLC68A1	Q14CX5	498
SLC37A3	MFSD11	O43934	498
SLC37A3	SLC67A2	Q8NBP5	496
SLC37A3	MFSD6	Q6ZSS7	466
SLC37A3	SLC71A2	Q5SR56	458
SLC37A3	SLC41A2	Q96JW4	445
SLC37A3	SETD4	Q9NVD3	445
SLC37A3	MKLN1	Q9UL63	443
SLC37A3	ST6GAL2	Q96JF0	438
SLC37A3	KDM7A	Q6ZMT4	417
SLC37A3	SLC20A1	Q8WUM9	406
SLC37A3	SLC35B1	P78383	406
SLC37A3	PCDH9	Q9HC56	404
SLC37A3	SLC5A7	Q9GZV3	401

IntAct

5 interactions, top by confidence:

A	B	Type	Score
FOXJ1	SLC37A3	psi-mi:“MI:0915”(physical association)	0.370
SLC37A3	ZNF177	psi-mi:“MI:0915”(physical association)	0.370
SLC37A3	APOB	psi-mi:“MI:0914”(association)	0.350
SLC37A3	PLXNB2	psi-mi:“MI:0914”(association)	0.350

BioGRID (95): SPRYD7 (Affinity Capture-MS), ATRAID (Affinity Capture-MS), CAV1 (Affinity Capture-MS), CLTCL1 (Affinity Capture-MS), APOB (Affinity Capture-MS), SLC25A46 (Affinity Capture-MS), MTX3 (Affinity Capture-MS), RNASEL (Affinity Capture-MS), TUBGCP2 (Affinity Capture-MS), ATP12A (Affinity Capture-MS), CYB5R3 (Affinity Capture-MS), DNAJC19 (Affinity Capture-MS), ARL15 (Affinity Capture-MS), SLC25A30 (Affinity Capture-MS), SLC5A3 (Affinity Capture-MS)

ESM2 similar proteins: A1L272, A2CER7, A2SWM2, A4IH46, A8WGF7, B0JZE1, B8AF63, O35440, O70451, O80605, P30638, P57057, Q08DX7, Q0IHM1, Q0VA82, Q10R54, Q2XWK0, Q2YDU8, Q3TIT8, Q3U9N9, Q5F3N0, Q5M7K3, Q5U3U7, Q5XGK0, Q63344, Q640L2, Q6DEJ6, Q6GPQ3, Q6YK44, Q6ZMD2, Q7SY29, Q7ZU13, Q8AVC3, Q8BH31, Q8K078, Q8NA29, Q8NCC5, Q8NHS3, Q8R070, Q8R0G7

Diamond homologs: O23596, P57057, Q17QZ3, Q3TIT8, Q58CV5, Q5F3N0, Q5M7K3, Q640L2, Q7SY29, Q8AVC3, Q8NCC5, Q8R070, Q8TED4, Q9C5L3, Q9SA71, Q9SB41, Q9SL56, Q9WU81, P42205, P9WG86, P9WG87

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

97 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	64
Likely benign	3
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

3159 predictions. Top by Δscore:

Variant	Effect	Δscore
7:140337348:TA:T	acceptor_gain	1.0000
7:140337350:C:CC	acceptor_gain	1.0000
7:140348623:TAC:T	donor_loss	1.0000
7:140348624:A:T	donor_loss	1.0000
7:140348628:ATGAT:A	donor_gain	1.0000
7:140348715:C:CT	acceptor_gain	1.0000
7:140348765:GTA:G	acceptor_gain	1.0000
7:140348766:TA:T	acceptor_gain	1.0000
7:140348767:ACTA:A	acceptor_loss	1.0000
7:140348768:C:CA	acceptor_loss	1.0000
7:140348768:C:CC	acceptor_gain	1.0000
7:140351269:TTAC:T	donor_loss	1.0000
7:140351270:TACCG:T	donor_loss	1.0000
7:140351271:A:AC	donor_gain	1.0000
7:140351271:ACC:A	donor_loss	1.0000
7:140351272:C:CC	donor_gain	1.0000
7:140351313:ATCG:A	donor_gain	1.0000
7:140351836:T:A	donor_gain	1.0000
7:140351865:C:CA	donor_gain	1.0000
7:140351866:C:A	donor_gain	1.0000
7:140352147:C:CC	acceptor_gain	1.0000
7:140355778:C:CT	acceptor_gain	1.0000
7:140355779:A:T	acceptor_gain	1.0000
7:140358634:GCATA:G	donor_loss	1.0000
7:140358635:CATA:C	donor_loss	1.0000
7:140358636:ATAC:A	donor_loss	1.0000
7:140358637:TA:T	donor_loss	1.0000
7:140358639:CCCGG:C	donor_gain	1.0000
7:140358647:T:A	donor_gain	1.0000
7:140369583:AACTT:A	donor_loss	1.0000

AlphaMissense

3214 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:140355742:A:G	W182R	1.000
7:140355742:A:T	W182R	1.000
7:140343443:C:T	G432D	0.999
7:140343563:C:T	G392E	0.999
7:140355720:C:A	G189V	0.999
7:140355721:C:G	G189R	0.999
7:140355747:C:T	G180D	0.999
7:140358686:A:G	W159R	0.999
7:140358686:A:T	W159R	0.999
7:140343433:G:C	S435R	0.998
7:140343433:G:T	S435R	0.998
7:140343435:T:G	S435R	0.998
7:140343437:C:T	G434E	0.998
7:140343438:C:A	G434W	0.998
7:140343447:C:G	D431H	0.998
7:140343529:A:C	S403R	0.998
7:140343529:A:T	S403R	0.998
7:140343531:T:G	S403R	0.998
7:140355720:C:T	G189D	0.998
7:140355721:C:A	G189C	0.998
7:140358684:C:A	W159C	0.998
7:140358684:C:G	W159C	0.998
7:140358694:G:A	S156F	0.998
7:140364491:C:G	G98R	0.998
7:140380390:A:C	S30R	0.998
7:140380390:A:T	S30R	0.998
7:140382439:T:G	S30R	0.998
7:140343444:C:G	G432R	0.997
7:140343455:C:T	G428E	0.997
7:140343461:A:T	V426D	0.997

dbSNP variants (sampled 300 via entrez): RS1000047037 (7:140389637 C>T), RS1000138083 (7:140390432 A>G), RS1000143169 (7:140350728 C>A,T), RS1000152851 (7:140397827 G>A), RS1000234230 (7:140370377 T>C), RS1000251328 (7:140397285 C>G,T), RS1000332899 (7:140377221 T>G), RS1000340152 (7:140338132 C>T), RS1000420178 (7:140390786 T>C), RS1000428948 (7:140384666 C>G), RS1000514242 (7:140364213 T>C), RS1000574835 (7:140372038 G>C,T), RS1000606050 (7:140371857 T>G), RS1000681725 (7:140333561 G>A,C), RS1000737436 (7:140370957 C>G)

Disease associations

OMIM: gene MIM:619137 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa	Strong	Autosomal recessive

Mondo (1): retinitis pigmentosa (MONDO:0019200)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC37 family of phosphosugar/phosphate exchangers

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases abundance, increases oxidation, affects cotreatment, decreases expression	2
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
beta-lapachone	increases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
nickel sulfate	decreases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
Resveratrol	increases expression, affects cotreatment	1
Acrolein	increases abundance, affects cotreatment, decreases expression, increases oxidation	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	decreases expression	1
Drugs, Chinese Herbal	increases expression	1
Estradiol	increases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Naphthoquinones	increases expression	1
Ozone	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
T-2 Toxin	decreases expression	1
Dronabinol	decreases expression	1
Tretinoin	decreases expression	1
Cyclosporine	increases expression	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1
Volatile Organic Compounds	affects cotreatment, decreases expression, increases oxidation	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4MV	HCT116-SLC37A3-KO-c11	Cancer cell line	Male
CVCL_D4MW	HCT116-SLC37A3-KO-c4	Cancer cell line	Male
CVCL_D4MX	HCT116-SLC37A3-KO-c9	Cancer cell line	Male
CVCL_E0NW	Ubigene HeLa SLC37A3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

234 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
NCT01068561	PHASE1	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa